Ibrutinib is a potent, irreversible and effective inhibitor of BTK that is taken orally, and was approved for indications in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) in 2013 and 2014 [17–19]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.